
PGY IV Chief Resident at Yale @bpthosp | @AASLDFoundation Emerging Liver Scholar 🏆 | Alum @HarvardChanSPH | GI/Hep 🪄 | Sports Lover ⚽️🏀🎾🏈| Researcher 👨🔬
Joined October 2021
- Tweets206
- Following241
- Followers201
- Likes382
Pinned Tweet
Thank you @AASLDFoundation
👏 Congratulations to Sarpong Boateng of Yale New Haven Health, Bridgeport Hospital (@SarpB44 of @BPTHOSP) — recipient of the #AASLDFoundation Raymond T. Chung #EmergingLiverScholar Award! #LiverTwitter bit.ly/41cL7Qk
Sarpong Boateng, MD, MPH retweeted
📣 Fri 12/4-12/5: Register now for Digestive Research and Education Excellence Aimed for Minorities (DREAM) conf at Morehouse!
@AmCollegeGastro
eventbrite.com/e/digestive-r…
Sarpong Boateng, MD, MPH retweeted
Excited to share our work at #TheLiverMeeting! 💚🤰
Stop by and see future GI Libby Bell presenting our findings:
In a cohort of 31 pregnancies among women with primary sclerosing cholangitis (#PSC), aspirin use was associated with fewer liver-related complications.
Promising early findings for an understudied population!
#AASLD #TLM2026
Sarpong Boateng, MD, MPH retweeted
🌟 Team LFN is making an impact at #TLM2026!
We’re excited to celebrate the incredible contributions of our Liver Fellow Network members!
👥 36 unique presenters
📊 67 presentations
🔬 56 posters
🎤 7 oral abstracts
🗣️ 4 academic debates
#LiverTwitter #Hepatology
Sarpong Boateng, MD, MPH retweeted
Check out this interesting #JMIR #Preprint: Explainable Artificial Intelligence for Predicting Significant Fibrosis in Steatotic Liver Disease: A Model Development Study preprints.jmir.org/preprint/… #digitalhealth via @jmirpub
Sarpong Boateng, MD, MPH retweeted
Genome sequencing in MASLD 🔥
Feeling grateful! 🙏🏾
#ACG2026
@AmCollegeGastro
@UMCapRegionIM
@YaleIMed
@SarpB44
@HealioGastro
📚 Excited to be part of the @LiverFellow community!
Looking forward to sharing our research at #ACG2026, learning from colleagues, and connecting with the GI & hepatology community in Nashville.
Grateful to LFN for highlighting our work!
See you in Music City! 🎸
@AmCollegeGastro
Our LFN leads are bringing their research to #ACG2026! 🎉
We’re excited to highlight their presentations and the great work they’ve been doing.
If you’re attending ACG, be sure to stop by, check out their research, and connect with them!
See you in Nashville! 👇
🧠 Sometimes, the most meaningful research questions begin with one patient.
A patient with MASLD + unrecognized depression struggling with treatment made me ask: How much depression are we missing in ACLD?
That question became a national study now published in @AGA_GHAdvances.
Among U.S. adults with ACLD:
➡️ ~1 in 7 had comorbid depression
➡️ Burden increased after the COVID-19 pandemic
➡️ Women & young adults particularly vulnerable
Liver care cannot stop at the liver.
📄 doi.org/10.1016/j.gastha.202…
#Hepatology #MentalHealth #LiverDisease
🚨 Obesity is reshaping liver transplantation.
Our latest study analyzed nearly 180,000 liver transplant recipients across more than 3 decades using the @UNOSNews transplant registry.
📆 1988–2022
📈 Mean BMI: 24.7 → 28.9 kg/m²
🔮 Projected BMI by 2050: 30.1 kg/m²
Incredibly proud to have led this work.
Grateful to @Bubu_Banini, @YaleFattyLiver & our entire team.
🔗 lnkd.in/gWyRRwJf
#LiverTransplant #Obesity #Hepatology
Sarpong Boateng, MD, MPH retweeted
On going GHANA’s FIRST ADVANCED ENDOSCOPY FELLOWSHIP PROGRAM at The Center of Excellence for Liver &
Digestive Health
@Tkothari13 @DrVeeral Nurse Olarere Omorinde
TRAINEES: Dr Akosua Agyen-Frimpong,
Dr Kenneth Tachi, Dr Agyei-Nkansah Adwoa
NURSES:
Derrick Ntow
Michael Obeng
Sarpong Boateng, MD, MPH retweeted
Please check out our review on @ACG_EBGI 🔔🔔⬇️
I am very grateful to Dr. @BilalMohammadMD for this opportunity.
“ESD vs TAMIS for Early Rectal Neoplasms
📜📋Question: Is endoscopic submucosal dissection (ESD) noninferior to transanal minimally invasive surgery (TAMIS) for preventing local recurrence after local resection of early rectal neoplasms?
❇️✂️✂️🔪Our Practice:
Patient selection and local expertise are key factors when choosing between ESD and TAMIS. Large rectal neoplasms need special consideration because of the risk of submucosal invasion. In addition, rectal surgeries are associated with higher morbidity as compared to colon surgeries.
Sarpong Boateng, MD, MPH retweeted
🧬 Do all Lynch syndrome genes behave the same? Maybe not!
In our study of 187 patients:
🔎 MSH2 → highest adenoma/SSL occurrence at baseline
📈 MSH6 → highest risk during surveillance
🌎 Socioeconomic disadvantage → higher odds of CRC
🏆 Another reason to look forward to #TLM2026!
Incredibly honored to receive the 2026 @AASLDFoundation Resident Research Award.
Join us in Denver as our team presents our work:
🏆 Resident Research Award
⭐ Poster of Distinction
🎤 Several oral & poster presentations
Spanning MASLD, precision medicine, pharmacogenomics & cardiometabolic liver disease.
See you at #TLM2026! 🏔️
#Hepatology #MASLD
🚨 Obesity is reshaping liver transplantation.
Our latest study analyzed ~180,000 liver transplant recipients across 3 decades using the @UNOSNews transplant registry.
📆 1988–2022
📈 Mean BMI: 24.7 → 28.9 kg/m²
🔮 Projected BMI by 2050: 30.1 kg/m²
Big thanks to @Bubu_Banini and @YaleFattyLiver for the support, as always.
📄 Full paper: mdpi.com/2673-4389/6/4/81
Can split liver transplantation help expand the donor pool without compromising outcomes?
Our latest study suggests it can, with appropriate graft selection and matching.
Proud to contribute to this national analysis of 840 adult split liver transplant recipients. Big thanks to @doctornikkid and @leandrosierraca.
#LiverTransplant #Hepatology #Transplantation
Read our latest paper:
pubmed.ncbi.nlm.nih.gov/4196…
Split liver transplant is still <1% of US adult LTs
UNOS analysis N= 840 recipients
•Right lobe 91.7% v. left lobe 79.6% 12-mo graft survival
•GRWR ≥0.8→outcomes match whole liver
•38% lower 12-mo mortality v. the waitlist
Sarpong Boateng, MD, MPH retweeted
Read our latest paper:
pubmed.ncbi.nlm.nih.gov/4196…
Split liver transplant is still <1% of US adult LTs
UNOS analysis N= 840 recipients
•Right lobe 91.7% v. left lobe 79.6% 12-mo graft survival
•GRWR ≥0.8→outcomes match whole liver
•38% lower 12-mo mortality v. the waitlist
































